Management of high-risk myelodysplastic syndromes

✍ Scribed by Francesco D. Pisani; Angela Rainaldi

• Book ID: 104375042
• Publisher: Elsevier Science
• Year: 2001
• Tongue: English
• Weight: 202 KB
• Volume: 40
• Category: Article
• ISSN: 1040-8428
• DOI: 10.1016/s1040-8428(01)00093-2

✦ Synopsis

The myelodysplastic syndromes (MDS) are a group of clonal disorders characterized by one or more cytopenias secondary to bone marrow dysfunction. The percentage of bone marrow blasts, the number of cytopenic cell lines and cytogenetics define more precisely clinical risk groups. In the high-risk MDS, the time for evolution to acute myeloid leukemia (AML) is between 0.2 and 1.1 years and the median survival has been evaluated between 0.4 and 1.2 years. Progress in the understanding the biology of MDS and the development of accurate prognostic classification systems have allowed a risk-adapted treatment strategy in individual patients. Some high-risk MDS patient categories may benefit from intensive cytotoxic treatment. Allogeneic stem cell